http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-335070-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4444e2fa52f6e2dd1e3f83fb2468227
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
filingDate 2004-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_653c74571f1c381f8091b32f7b139bc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3388abd6992941fb799275834a92a383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e3f74ba4e6f9cc3d80275feba051378
publicationDate 2014-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NO-335070-B1
titleOfInvention Timed sustained release multiparticulate dosage forms of propranolol
abstract A unit dosage form, such as a capsule or the like, for delivering drugs to the body in a circadian manner, which includes one or more populations of propranolol-containing particles (beads, pellets, granules, ether). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined delay time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration - time profile, which varies according to physiological needs during the day, i.e. mimicking the circadian rhythm and severity manifestation of a cardiovascular disease and pharmacodynamic and pharmacodynamic disease based on in vivo correlations.
priorityDate 2001-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559261
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554785

Total number of triples: 34.